

Biosynthesis of yatein in *Anthriscus sylvestris* †Norikazu Sakakibara, Shiro Suzuki, Toshiaki Umezawa* and Mikio Shimada
Wood Research Institute, Kyoto University, Uji, Kyoto 611-0011, Japan

Received 23rd April 2003, Accepted 27th May 2003

First published as an Advance Article on the web 20th June 2003

Little is known about the biosynthesis of yatein, in spite of its importance as a typical heartwood lignan and a key biosynthetic intermediate of the antitumor lignan podophyllotoxin. The present study, based on individual administration of [¹³C]phenylalanine and deuterium labelled lignans and simultaneous administration of two distinct lignans labelled with deuterium atoms to *Anthriscus sylvestris*, established the two independent branch pathways from matairesinol, one to afford yatein *via* thujaplicatin, 5-methylthujaplicatin, and 4,5-dimethylthujaplicatin and the other to bursehernin *via* pluviatolide. The latter pathway did not lead to yatein, eliminating the presence of a metabolic grid from matairesinol to yatein.

Introduction

An antitumor lignan, podophyllotoxin, has been successfully used as the starting material for semi-synthetic anti-cancer drugs, etoposide and teniposide.¹⁻⁶ Podophyllotoxin is isolated from herbaceous perennial *Podophyllum* plants.^{5,7,8} However, due to the limited supply of the plants, much attention has been focused on the availability and biosynthesis of the lignan.^{1,3,5,8}

In the 1980s, Dewick and co-workers reported a series of detailed feeding experiments with radio-labelled precursors and revealed the pathways from yatein (**11**) to podophyllotoxin and its congeners *via* deoxypodophyllotoxin (=desoxypodophyllotoxin, anthricin).⁹⁻¹² Next, they showed that matairesinol (**2**) is metabolized to podophyllotoxin and proposed that (**11**) was the possible intermediate in the conversion of (**2**) to podophyllotoxin.¹³ During the last decade, significant progress has been made in the biosynthetic studies of lignans, and the biosynthesis of matairesinol (**2**) from coniferyl alcohol has been established.¹⁴ Recently, several enzymes involved in the transformation of deoxypodophyllotoxin to podophyllotoxin, β-peltatin, and 5-methoxypodophyllotoxin have been isolated.¹⁵⁻¹⁷ These data allow us to draw the outline of biosynthetic pathways for podophyllotoxin derivatives as in Fig. 1. Briefly, the dimerization of coniferyl alcohol, followed by three metabolic steps gives rise to matairesinol (**2**). Then, matairesinol (**2**) is transformed to yatein (**11**) which is in turn converted to podophyllotoxin congeners. However, the pathway from matairesinol (**2**) to yatein (**11**) remains unknown.

Besides the role for the precursor of podophyllotoxin, yatein (**11**) is also of importance as a heartwood lignan.¹⁸ Heartwood is the colored region of the inner part of tree trunks, and its formation is a metabolic event specific to woody plants, as it does not operate in herbaceous plants. Recently, metabolic engineering of trees has been developed significantly. For example, a transgenic aspen (*Populus tremuloides*) with less lignin and higher cellulose contents has been successfully produced by Chiang and co-workers.¹⁹ These developments were achieved with the aid of the knowledge of herbaceous plant molecular biology. Now, it is necessary to exploit knowledge of molecular mechanisms for metabolic events specific to woody plants in order to accelerate metabolic engineering of trees. Although nothing is known about the molecular mechanisms, the facts that biosynthesis of lignans, norlignans and related compounds are involved in heartwood formation implies that




Fig. 1 A proposed biosynthetic pathway from coniferyl alcohol to podophyllotoxin. **2**: matairesinol, **11**: yatein. Solid arrow: established in previous reports. Broken arrow: established in this report.

the molecular mechanisms of their biosynthesis can be a clue to help us elucidate heartwood formation mechanisms.

*Anthriscus sylvestris*²⁰⁻²⁶ is a good source of yatein (**11**) and deoxypodophyllotoxin, both of which are effective precursors of podophyllotoxin.⁹⁻¹¹ In addition, angeloyl podophyllotoxin has been isolated from this species.²⁷ The high content of yatein (**11**) and deoxypodophyllotoxin as well as the good growth behaviour stimulated us to employ *A. sylvestris* as a plant

† A part of this work was performed as a part of the R & D Project of Industrial Science and Technology Frontier Program supported by NEDO (New Energy and Industrial Technology Development Organization).




Fig. 2 A proposed biosynthetic pathway of yatein in *Anthriscus sylvestris*. 1: secoisolariciresinol, 2: matairesinol, 3: thujaplicatin, 4: 5-methylthujaplicatin, 5: 4,5-dimethylthujaplicatin, 6: pluviatolide, 7: 5-hydroxypluviatolide, 8: 4-demethylatein, 9: bursehernin, 10: 5-demethylatein, 11: yatein. Solid arrow: proposed biosynthetic pathway in *Anthriscus sylvestris*. Broken arrow: physiologically insignificant pathway.

material for the study of yatein biosynthesis, and we have recently reported the survey of lignans in this species.²⁶

The conversion of matairesinol (**2**) to yatein (**11**) involves four steps: 5-hydroxylation, dual methylation at C4OH and C5OH, and methylenedioxy bridge formation at C3' and C4' (Fig. 2). Many possible orders of their occurrence can be envisaged suggesting that a metabolic grid might be present in the transformation. The aim of the present study is to identify the physiologically important biosynthetic pathway from matairesinol (**2**) to yatein (**11**).

Herein, we report the administration of [¹³C]phenylalanine and a series of deuterium labelled lignans to *A. sylvestris*, and discuss the biosynthetic pathway from matairesinol (**2**) to yatein (**11**) in this species.

Results

Lignans in *Anthriscus sylvestris*

Recently, we have surveyed lignans occurring in *Anthriscus sylvestris*:²⁶ GC-MS analysis of the MeOH extracts of the plant showed the presence of lignans, lariciresinol, secoisolariciresinol (**1**), matairesinol (**2**), pluviatolide (**6**), yatein (**11**), hinokinin, nemerosin, and deoxypodophyllotoxin. Additionally, the existence of small amounts of bursehernin (**9**) was suggested by mass chromatography.²⁶ Further GC-MS analysis in the present study indicated the presence of 5-methylthujaplicatin (**4**) and 4,5-dimethylthujaplicatin (**5**) in the MeOH extracts, which were identified by comparing their mass spectra [5-methyl-

thujaplicatin (**4**) (TMS ether): m/z (EI) 532 (M^+ , 100%), 239 (84.1), 209 (26.0); 4,5-dimethylthujaplicatin (**5**) (TMS ether): m/z (EI) 474 (M^+ , 100%), 209 (71.0), 181 (56.0)] and retention times on GC with those of chemically synthesized authentic samples. In addition, yatein (**11**) and deoxypodophyllotoxin were isolated from the MeOH extracts and identified by comparison of the ¹H-NMR and mass spectrum (data not shown) with those of the literature data.²⁸

Feeding experiments

Small scale feeding experiments. Nine lignans labelled with deuterium atoms at the methoxy groups, (\pm)-[3-OC²H₃]matairesinols (**2-d₃**), (\pm)-[3-OC²H₃]thujaplicatins (**3-d₃**), (\pm)-[3,5-(OC²H₃)₂]-5-methylthujaplicatins (**4-d₆**), (\pm)-[3,5-(OC²H₃)₂]-4,5-dimethylthujaplicatins (**5-d₆**), (\pm)-[3-OC²H₃]pluviatolides (**6-d₃**), (\pm)-[3-OC²H₃]-5-hydroxypluviatolides (**7-d₃**), (\pm)-[3,5-(OC²H₃)₂]-4-demethylateins (**8-d₆**), (\pm)-[3,4-(OC²H₃)₂]-bursehernins (**9-d₆**), and (\pm)-[3,4-(OC²H₃)₂]-5-demethylateins (**10-d₆**), were fed individually to young shoots of *A. sylvestris* (0.4 mg of each lignan to one shoot). Results of GC-MS analysis of the MeOH extracts obtained following the administration are summarized in Tables 1–3. Table 1 shows the molecular ion and important daughter ion regions of unlabelled authentic yatein (**11**) and of this lignan obtained following the administration: unlabelled yatein (**11**) gives a molecular ion at m/z 400 and principal daughter ions at m/z 181 and 135 which are derived from benzylic cleavage of A- and B-rings (Fig. 2), respectively. When the lignans labelled

Table 1 Mass tables of molecular-ion and principal daughter-ion regions of lignan (**11**) obtained following administration of ^{13}C - or deuterium-labelled precursors into *A. sylvestris*.

Yatein (11)														
Relative intensity (%)														
<i>m/z</i>	Unlabelled	Administrated labelled compounds												
		$^{13}\text{C}_6$ Phen	1- <i>d</i> ₃	2- <i>d</i> ₃	3- <i>d</i> ₃	4- <i>d</i> ₆	5- <i>d</i> ₆	6- <i>d</i> ₃	7- <i>d</i> ₃	8- <i>d</i> ₆	9- <i>d</i> ₆	10- <i>d</i> ₆	1- <i>d</i> ₅ + 3- <i>d</i> ₃	1- <i>d</i> ₅ + 6- <i>d</i> ₃
135	30.6 ^b	37.2 ^b	43.4 ^b	38.2 ^b	42.6 ^b	47.0 ^b	39.9 ^b	33.5 ^b	46.3 ^b	42.9 ^b	30.3 ^b	36.6 ^b	41.8 ^b	41.1 ^b
136	13.5	12.7	16.3	14.1	13.1	13.3	13.6	12.4	16.0	12.7	10.6	13.9	12.9	13.1
137	4.7	5.2	6.7	3.5	4.7	5.2	3.3	3.3	8.7	5.4	4.1	6.2	6.6	5.4
138	3.1	2.0	2.7	1.6	2.0	2.5	2.6	1.4	2.8	2.1	2.1	3.6	1.9	1.5
139	1.3	1.6	2.1	0.9	2.5	1.2	1.0	0.7	3.8	1.9	3.4	1.0	2.2	1.6
140	1.0	0.7	0.4	0.0	1.0	0.7	0.0	0.3	1.5	0.5	0.0	0.0	1.0	0.5
141	0.7	4.5^b	0.4	0.0	1.1	1.3	0.0	0.6	1.4	0.2	0.0	0.0	1.5	0.5
142	1.1	1.4	0.3	0.2	0.1	1.0	0.3	0.0	0.1	0.2	2.4	0.0	0.4	0.3
143	0.4	1.0	0.9	0.7	0.9	0.4	0.9	0.4	0.5	0.6	1.2	0.0	0.8	0.8
181	100.0 ^a	100.0 ^a	100.0 ^a	100.0 ^a	100.0 ^a	100.0 ^a	100.0 ^a	100.0 ^a	100.0 ^a	100.0 ^a	100.0 ^a	100.0 ^a	100.0 ^a	100.0 ^a
182	48.9	58.5	56.8	51.2	55.3	55.6	53.2	61.9	61.3	62.7	54.9	60.2	53.3	54.4
183	5.6	7.9	7.4	7.0	6.9	6.3	6.7	6.7	8.3	8.2	8.3	10.7	7.0	7.6
184	1.2	0.8	10.3^a	0.0	11.7^a	1.0	1.5	1.4	19.3^a	2.3	1.8	1.2	11.8^a	2.0
185	2.2	1.3	5.0	1.5	6.7	1.0	0.3	0.1	11.1	0.6	0.0	0.0	7.4	1.6
186	0.8	2.1	1.0	0.9	1.7	1.0	0.9	0.4	2.1	0.1	0.0	0.0	8.2^a	3.5^a
187	0.9	17.7^a	0.9	0.9	0.5	16.9^a	4.2^a	0.1	1.3	12.0^a	0.0	12.3^a	3.7	2.3
188	1.8	7.9	1.1	1.0	2.1	9.9	2.4	1.9	2.0	8.6	0.0	8.8	1.2	0.6
189	2.2	2.3	2.9	2.1	1.8	2.5	2.7	2.7	3.1	2.8	2.9	4.6	1.8	3.2
400	70.1 ^c	78.0 ^c	74.2 ^c	68.9 ^c	71.7 ^c	73.7 ^c	67.0 ^c	75.2 ^c	93.7 ^c	92.1 ^c	76.6 ^c	88.9 ^c	75.2 ^c	76.4 ^c
401	19.8	20.2	21.7	19.1	19.8	21.4	20.6	18.6	22.2	23.0	16.6	21.9	21.9	21.2
402	3.7	4.8	6.7	5.5	4.2	4.6	3.8	5.1	4.5	4.6	4.3	6.3	4.6	5.3
403	0.0	1.4	9.0^c	2.5	7.8^c	1.9	1.8	1.6	16.1^c	2.1	0.0	1.3	10.3^c	1.6
404	0.0	0.0	2.4	1.3	3.2	1.6	0.8	0.6	4.6	1.7	0.0	0.0	4.4	2.0
405	0.0	1.1	0.7	0.4	0.6	1.6	1.0	0.5	1.8	0.0	0.0	0.0	7.3^c	3.4^c
406	0.0	3.9^c	0.7	0.0	0.0	12.9^c	2.5^c	0.5	0.0	13.3^c	0.0	9.3^c	1.8	2.3
407	0.0	1.5	0.3	0.2	0.7	4.5	1.6	0.0	0.0	4.7	0.0	3.0	0.6	0.8
408	0.0	0.8	0.0	0.0	0.0	0.9	0.4	0.4	0.0	1.5	0.0	0.0	1.3	0.0
412	0.0	13.0^c	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0
413	0.0	1.6	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.0
414	0.0	0.3	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0

$^{13}\text{C}_6$ Phen: [*ring*- $^{13}\text{C}_6$]phenylalanine, 1-*d*₃: (±)-[3-OC²H₃]secoisolaricresinols, 2-*d*₃: (±)-[3-OC²H₃]matairesinols, 3-*d*₃: (±)-[3-OC²H₃]thujaplicatins, 4-*d*₆: (±)-[3,5-(OC²H₃)₂]-5-methylthujaplicatins, 5-*d*₆: (±)-[3,5-(OC²H₃)₂]-4,5-dimethylthujaplicatins, 6-*d*₃: (±)-[3-OC²H₃]pluviatolides, 7-*d*₃: (±)-[3-OC²H₃]-5-hydroxypluviatolides, 8-*d*₆: (±)-[3,5-(OC²H₃)₂]-4-demethylateins, 9-*d*₆: (±)-[3,4-(OC²H₃)₂]burshehmin, 10-*d*₆: (±)-[3,4-(OC²H₃)₂]-5-demethylateins. ^a Ions formed after benzylic cleavages of A-ring. ^b Ions formed after benzylic cleavages of B-ring. ^c Molecular ions. Bold-faced: extra ions due to incorporation of ^{13}C or deuterium atoms.

with six deuterium atoms at the two methoxy groups on the A-ring (Fig. 2), (±)-[3,5-(OC²H₃)₂]-5-methylthujaplicatins (4-*d*₆), (±)-[3,5-(OC²H₃)₂]-4,5-dimethylthujaplicatins (5-*d*₆), (±)-[3,5-(OC²H₃)₂]-4-demethylateins (8-*d*₆), and (±)-[3,4-(OC²H₃)₂]-5-demethylateins (10-*d*₆), were administrated, the extra ions at *m/z* 406 and 187 were observed in the mass spectra of (**11**), while in the feeding of the lignans with one OC²H₃ group and three deuterium atoms, (±)-[3-OC²H₃]thujaplicatins (3-*d*₃) and (±)-[3-OC²H₃]-5-hydroxypluviatolides (7-*d*₃), extra ions at *m/z* 403 and 184 were observed. These results unequivocally indicate the conversion of (3-*d*₃), (4-*d*₆), (5-*d*₆), (7-*d*₃), (8-*d*₆), and (10-*d*₆) to yatein labelled with three or six deuterium atoms (11-*d*₃ or 11-*d*₆). However, no evidence of isotope incorporation into yatein (**11**) was observed when (±)-[3-OC²H₃]matairesinols (2-*d*₃), (±)-[3-OC²H₃]pluviatolides (6-*d*₃), and (±)-[3,4-(OC²H₃)₂]burshehmin (9-*d*₆) were administrated (Table 1). Similarly, Tables 2 and 3 show mass spectral data of the other lignans obtained following the administration.

Thus, these data demonstrate the conversions of the labelled precursors into several lignans summarized as follows:

(±)-[3-OC²H₃]matairesinols (2-*d*₃) → [²H₃]pluviatolide (6-*d*₃) (Table 3), and [²H₃]burshehmin (9-*d*₆) (Table 3)

(±)-[3-OC²H₃]thujaplicatins (3-*d*₃) → [²H₃]-5-methylthujaplicatin (4-*d*₃) (Table 2), [²H₃]-4,5-dimethylthujaplicatin (5-*d*₃) (Table 2), and [²H₃]yatein (11-*d*₃) (Table 1)

(±)-[3,5-(OC²H₃)₂]-5-methylthujaplicatins (4-*d*₆) → [²H₆]-4,5-dimethylthujaplicatin (5-*d*₆) (Table 2), and [²H₆]yatein (11-*d*₆) (Table 1)

(±)-[3,5-(OC²H₃)₂]-4,5-dimethylthujaplicatins (5-*d*₆) → [²H₆]yatein (11-*d*₆) (Table 1)

(±)-[3-OC²H₃]pluviatolides (6-*d*₃) → [²H₃]burshehmin (9-*d*₆) (Table 3)

(±)-[3-OC²H₃]-5-hydroxypluviatolides (7-*d*₃) → [²H₃]-4-demethylatein (8-*d*₃) (Table 3), [²H₃]-5-demethylatein (10-*d*₃) (Table 3), and [²H₃]yatein (11-*d*₃) (Table 1)

(±)-[3,5-(OC²H₃)₂]-4-demethylateins (8-*d*₆) → [²H₆]yatein (11-*d*₆) (Table 1)

(±)-[3,4-(OC²H₃)₂]-5-demethylateins (10-*d*₆) → [²H₆]yatein (11-*d*₆) (Table 1)

Large scale feeding experiments. The following compounds were administered to *A. sylvestris* in the same manner as the small scale experiments, but scaled up ten times (4 mg of each compound to 10 shoots): [*ring*- $^{13}\text{C}_6$]phenylalanine, (±)-[3-OC²H₃]secoisolaricresinols (1-*d*₃), (±)-[3-OC²H₃]matairesinols (2-*d*₃), (±)-[3-OC²H₃]pluviatolides (6-*d*₃), and (±)-[3,4-(OC²H₃)₂]burshehmin (9-*d*₆). GC-MS analysis confirmed the transformation [(2-*d*₃) → (6-*d*₃) and (9-*d*₆); and (6-*d*₃) → (9-*d*₆)] as in the small scale experiments (data not shown). In addition, the conversions listed below were detected by GC-MS analysis.

[*ring*- $^{13}\text{C}_6$]phenylalanine → [$^{13}\text{C}_{12}$] and [$^{13}\text{C}_6$]matairesinol (2- $^{13}\text{C}_{12}$ and $^{13}\text{C}_6$) (Table 2), [$^{13}\text{C}_{12}$] and [$^{13}\text{C}_6$]-5-methylthujaplicatin (4- $^{13}\text{C}_{12}$ and $^{13}\text{C}_6$) (Table 2), [$^{13}\text{C}_{12}$] and [$^{13}\text{C}_6$]-4,5-dimethylthujaplicatin (5- $^{13}\text{C}_{12}$ and $^{13}\text{C}_6$) (Table 2), [$^{13}\text{C}_{12}$] and [$^{13}\text{C}_6$]pluviatolide (6- $^{13}\text{C}_{12}$ and $^{13}\text{C}_6$) (Table 3), [$^{13}\text{C}_{12}$]

Table 2 Mass tables of molecular-ion and principal daughter-ion regions of lignans (**2**), (**4**) and (**5**) obtained following administration of ^{13}C - or deuterium-labelled precursors into *A. sylvestris*

Matairesinol (2) (TMS ether)				5-Methylthujaplicatin (4) (TMS ether)					4,5-Dimethylthujaplicatin (5) (TMS ether)					
Relative intensity (%)				Relative intensity (%)					Relative intensity (%)					
<i>m/z</i>	Unlabelled	Administrated labelled compounds		<i>m/z</i>	Unlabelled	Administrated labelled compounds			<i>m/z</i>	Unlabelled	Administrated labelled compounds			
		$^{13}\text{C}_6$ Phe	1-d₃			$^{13}\text{C}_6$ Phe	1-d₃	3-d₃			$^{13}\text{C}_6$ Phe	1-d₃	3-d₃	4-d₆
209	100.0 ^{a,b}	21.9 ^{a,b}	100.0 ^{a,b}	209	54.4 ^b	26.6 ^b	16.3 ^b	8.2 ^b	209	46.4 ^b	30.8 ^b	27.1 ^b	17.3 ^b	23.3 ^b
210	29.3	7.8	28.3	210	16.7	6.1	3.7	2.0	210	25.2	18.0	15.0	3.5	15.4
211	8.4	3.1	9.5	211	5.9	2.5	1.2	4.0	211	6.2	6.7	3.6	0.0	0.0
212	1.6	0.3	71.4^a	212	0.0	7.3	8.2	2.0	212	1.3	4.3	33.1	15.8	12.6
213	0.4	1.9	18.3	213	0.0	5.4	3.4	7.4	213	0.0	0.0	22.7	9.9	10.4
214	0.0	1.7	5.3	214	0.0	4.5	3.5	2.2	214	1.5	6.2	3.2	0.0	0.5
215	0.3	18.6^{a,b}	0.0	215	0.0	11.4^b	0.2	0.0	215	0.0	21.2^b	2.9	0.0	4.9
216	0.9	4.7	0.0	216	0.0	4.0	0.7	0.0	216	1.7	5.3	1.4	13.5	3.0
217	2.7	2.8	1.6	217	0.0	5.2	0.2	0.0	217	2.0	0.8	1.8	0.0	0.0
502	58.4 ^c	100.0 ^c	28.8 ^c	239	83.0 ^a	21.2 ^a	31.3 ^a	9.9 ^a	181	100.0 ^a	74.0 ^a	100.0 ^a	100.0 ^a	88.5 ^a
503	26.7	46.7	15.6	240	31.2	11.9	13.7	6.0	182	73.1	36.3	68.0	55.0	78.5
504	11.4	20.6	12.3	241	10.5	3.4	5.6	4.1	183	8.7	16.5	11.2	12.2	17.7
505	3.6	9.5	84.0^c	242	3.4	1.3	10.0^a	4.5^a	184	1.1	0.0	24.2^a	42.6^a	3.5
506	1.4	3.2	33.4	243	11.4	0.2	3.7	3.7	185	0.0	2.8	13.3	24.7	0.0
507	0.5	4.8	13.0	244	1.4	0.0	1.5	1.7	186	0.5	0.0	4.8	8.8	0.0
508	0.0	9.1^c	0.0	245	0.0	10.0^a	1.1	0.0	187	0.0	33.9^a	1.3	2.9	30.0^a
509	0.4	9.4	0.0	246	0.0	9.0	1.3	7.0	188	0.6	21.7	2.4	9.3	13.0
510	0.2	5.6	0.0	247	2.9	2.9	4.9	0.0	189	2.0	0.0	3.0	14.7	2.0
514	0.1	9.4^c	0.0	532	100.0 ^c	100.0 ^c	28.1 ^c	14.2 ^c	474	95.9 ^c	100.0 ^c	36.7 ^c	24.1 ^c	38.3 ^c
515	0.0	4.2	0.0	533	46.5	46.4	14.1	12.5	475	35.8	38.3	14.2	16.7	27.0
516	0.0	2.6	0.0	534	21.5	8.4	14.9	4.9	476	11.3	0.0	10.3	0.0	8.6
				535	2.1	0.0	35.1^c	10.4^c	477	1.5	9.0	99.1^c	12.3^c	0.0
				536	0.0	0.0	17.8	4.0	478	0.0	0.0	33.6	0.0	0.0
				537	0.0	0.0	6.1	0.0	479	0.0	7.7	16.2	0.0	0.0
				538	0.0	9.6^c	0.0	0.0	480	0.0	20.5^c	5.8	0.0	28.8^c
				539	0.0	8.3	0.0	0.0	481	0.0	9.3	1.9	0.0	15.1
				540	0.0	0.0	0.0	0.0	482	0.0	2.5	0.0	0.0	0.0
				544	0.0	20.3^c	0.0	0.0	486	0.0	30.8^c	1.4	0.0	0.0
				545	0.0	0.0	0.0	0.0	487	0.0	5.5	0.0	0.0	0.0
				546	0.0	0.0	0.0	0.0	488	0.0	3.1	0.0	0.0	0.0

$^{13}\text{C}_6$ Phe: [ring- $^{13}\text{C}_6$]phenylalanine, **1-d₃**: (\pm)-[3-OC $^2\text{H}_3$]secoisolaricresinols, **3-d₃**: (\pm)-[3-OC $^2\text{H}_3$]thujaplicatins, **4-d₆**: (\pm)-[3,5-(OC $^2\text{H}_3$) $_2$]-5-methylthujaplicatins. ^a Ions formed after benzylic cleavages of A ring. ^b Ions formed after benzylic cleavages of B-ring. ^c Molecular ions. Bold-faced: extra ions due to incorporation of ^{13}C or deuterium atoms.

Table 3 Mass tables of molecular-ion and principal daughter-ion regions of lignans (**6**), (**8**)–(**10**) obtained following administration of ^{13}C - or deuterium-labelled precursors into *A. sylvestris*

Pluviatolide (6) (TMS ether)					4-Demethyl-yatein (8) (TMS ether)			Bursehernin (9)					5-Demethyl-yatein (10) (TMS ether)			
Relative intensity (%)					Relative intensity (%)			Relative intensity (%)					Relative intensity (%)			
<i>m/z</i>	Unlabelled	Administrated labelled compounds			<i>m/z</i>	Unlabelled	Administrated labelled compounds	<i>m/z</i>	Unlabelled	Administrated labelled compounds				<i>m/z</i>	Unlabelled	Administrated labelled compounds
		$^{13}\text{C}_6$ Phe	1-d₃	2-d₃			7-d₃			$^{13}\text{C}_6$ Phe	1-d₃	2-d₃	6-d₃			7-d₃
135	21.7 ^b	9.5 ^b	11.8 ^b	8.1 ^b	135	20.0 ^b	48.7 ^b	135	26.2 ^b	28.5 ^b	13.7 ^b	23.6 ^b	21.4 ^b	135	40.9 ^b	17.7 ^b
136	4.1	5.6	1.6	3.2	136	4.9	15.0	136	10.4	14.2	11.2	10.5	6.8	136	7.2	6.2
137	3.4	0.2	2.4	0.5	137	3.9	6.2	137	3.0	7.0	2.5	2.6	3.1	137	2.4	4.7
138	0.0	3.7	0.0	0.0	138	0.7	3.8	138	1.4	2.9	0.7	0.6	0.0	138	0.5	0.0
139	0.8	0.0	2.9	0.0	139	0.8	2.3	139	0.4	0.9	1.3	0.7	0.2	139	0.6	0.0
140	0.6	0.1	0.8	0.3	140	0.0	4.1	140	0.1	0.4	3.3	1.3	0.0	140	0.4	0.0
141	0.0	1.0^b	1.8	0.0	141	0.0	2.3	141	0.2	9.8^b	1.1	1.5	0.2	141	0.4	0.0
142	1.3	0.1	0.3	0.0	142	0.3	2.9	142	0.2	3.9	0.0	0.2	1.0	142	0.0	0.0
143	0.6	0.1	0.0	0.0	143	0.3	0.0	143	0.5	3.5	0.0	0.3	0.4	143	0.7	0.2
209	100.0 ^a	7.0 ^a	100.0 ^a	24.3 ^a	239	100.0 ^a	0.0	151	100.0 ^a	47.4 ^a	61.4 ^a	5.5 ^a	36.3 ^a	239	87.7 ^a	0.0
210	20.4	3.2	30.1	16.2	240	33.6	0.0	152	17.8	7.2	12.0	1.7	6.8	240	80.3	0.0
211	7.6	0.4	10.0	5.7	241	9.0	0.0	153	1.9	1.5	7.4	2.3	3.9	241	17.9	0.0
212	2.9	0.9	57.0^a	100.0^a	242	2.1	19.6^a	154	0.4	2.6	28.8^a	100.0^a	100.0^a	242	5.2	59.5^a
213	0.8	1.0	14.5	19.0	243	1.1	11.9	155	0.0	2.3	7.0	16.6	14.8	243	0.9	54.9
214	0.0	0.0	2.9	5.1	244	0.3	0.0	156	0.4	2.3	1.6	2.1	1.6	244	0.0	20.2
215	2.5	7.0^a	0.6	0.0	245	0.8	0.0	157	0.3	26.0^a	0.0	0.4	0.0	245	0.4	0.0
216	0.7	1.1	2.1	1.4	246	0.9	0.0	158	0.5	6.7	0.1	0.3	0.0	246	0.7	0.0
217	2.9	0.9	9.0	5.1	247	2.8	2.9	159	0.6	4.6	2.6	0.5	0.1	247	2.5	0.0
428	57.5 ^c	6.4 ^c	3.9 ^c	2.1 ^c	458	88.8 ^c	0.0	370	50.0 ^c	26.1 ^c	29.7 ^c	3.8 ^c	20.1 ^c	458	100.0 ^c	0.0
429	18.8	4.3	3.8	0.8	459	30.4	0.0	371	14.5	5.0	7.7	1.3	5.0	459	34.6	0.0
430	7.5	3.5	1.0	1.1	460	10.1	0.0	372	3.0	2.7	4.0	2.3	4.1	460	12.4	0.0
431	1.0	0.0	7.3^c	22.0^c	461	2.9	25.4^c	373	1.0	1.7	17.1^c	42.4^c	43.4^c	461	3.5	100.0^c
432	0.0	1.4	0.9	6.9	462	1.5	8.8	374	0.3	0.0	7.3	12.1	11.3	462	1.1	24.4
433	0.0	0.0	0.0	3.0	463	1.0	0.0	375	0.3	0.0	1.8	3.0	2.0	463	0.4	28.2
434	0.0	3.7^c	1.4	1.6	464	0.4	0.0	376	0.1	4.4^c	0.0	0.9	1.5	464	0.3	0.0
435	0.0	1.1	0.0	0.7	465	0.4	0.0	377	0.0	2.4	0.0	0.4	0.0	465	0.0	0.0
436	0.0	1.4	0.0	0.3	466	0.0	0.0	378	0.0	0.0	0.0	0.1	0.5	466	0.0	0.0
440	0.0	4.4^c	0.0	1.2	470	0.0	0.0	382	0.0	11.0^c	0.0	0.0	0.0	470	0.0	0.0
441	0.0	2.6	1.5	0.6	471	0.0	0.0	383	0.0	4.0	0.4	0.0	0.0	471	0.0	0.0
442	0.0	0.9	1.3	0.0	472	0.0	0.0	384	0.0	0.7	0.0	0.0	0.0	472	0.0	0.0

$^{13}\text{C}_6$ Phe: [*ring*- $^{13}\text{C}_6$]phenylalanine, **1-d₃**: (\pm)-[3-OC²H₃]secoisolaricresinols, **2-d₃**: (\pm)-[3-OC²H₃]matairesinols, **6-d₃**: (\pm)-[3-OC²H₃]pluviatolides, **7-d₃**: (\pm)-[3-OC²H₃]-5-hydroxypluviatolides. ^a Ions formed after benzylic cleavages of A-ring. ^b Ions formed after benzylic cleavages of B-ring. ^c Molecular ions. Bold-faced: extra ions due to incorporation of ^{13}C or deuterium atoms.

and [$^{13}\text{C}_6$]burshehnerin (**9**- $^{13}\text{C}_{12}$ and $^{13}\text{C}_6$) (Table 3), and [$^{13}\text{C}_{12}$] and [$^{13}\text{C}_6$]yatein (**11**- $^{13}\text{C}_{12}$ and $^{13}\text{C}_6$) (Table 1)

(\pm)-[3- OC^2H_3]secoisolariciresinols (**1**- d_3) \rightarrow [$^2\text{H}_3$]matairesinol (**2**- d_3) (Table 2), [$^2\text{H}_3$]thujaplicatin (**3**- d_3), [$^2\text{H}_3$]-5-methylthujaplicatin (**4**- d_3) (Table 2), [$^2\text{H}_3$]-4,5-dimethylthujaplicatin (**5**- d_3) (Table 2), [$^2\text{H}_3$]pluviatolide (**6**- d_3) (Table 2), [$^2\text{H}_3$]-burshehnerin (**9**- d_3) (Table 3), and [$^2\text{H}_3$]yatein (**11**- d_3) (Table 1)

(\pm)-[3- OC^2H_3]matairesinols (**2**- d_3) \rightarrow [$^2\text{H}_3$]thujaplicatin (**3**- d_3)

The deuterium incorporation into thujaplicatin (**3**) was further confirmed by selected ion monitoring (SIM). The SIM chromatograms of thujaplicatin (TMS ether) obtained following administration of (**1**- d_3) and (**2**- d_3) clearly indicate that the molecular ion of unlabelled (**3**) at m/z 590 and the fragment ion at m/z 297 due to the benzylic cleavage of A-ring of unlabelled (**3**) are accompanied by extra ions at m/z 593 and 300, respectively, indicating clearly the formation of [$^2\text{H}_3$]thujaplicatin (**3**- d_3) (Figs. 4-B and -C).

On the other hand, no evidence was obtained for the formation of ^{13}C -labelled [$^{13}\text{C}_{12}$] or [$^{13}\text{C}_6$]-5-hydroxypluviatolide (**7**- $^{13}\text{C}_{12}$ or $^{13}\text{C}_6$), [$^{13}\text{C}_{12}$] or [$^{13}\text{C}_6$]-4-demethylatein (**8**- $^{13}\text{C}_{12}$ or $^{13}\text{C}_6$), or [$^{13}\text{C}_{12}$] or [$^{13}\text{C}_6$]-5-demethylatein (**10**- $^{13}\text{C}_{12}$ or $^{13}\text{C}_6$) from [$\text{ring-}^{13}\text{C}_6$]phenylalanine. Thus, as shown in Fig. 5, neither endogenous unlabelled (**7**), (**8**), and (**10**) which have molecular ions at m/z 516, 458 and 458 (TMS ether), respectively, nor the lignans labelled with twelve or six ^{13}C atoms were detected.

Similarly, no deuterium-labelled (**7**- d_3), (**8**- d_3), and (**10**- d_3 or d_6) from any of the deuterium labelled lignans, (**1**- d_3), (**2**- d_3), (**6**- d_3), and (**9**- d_6) were observed. For example, Fig. 6 demonstrates that neither unlabelled, endogenous 5-hydroxypluviatolide (**7**) nor deuterium-labelled (**7**) was detected following administration of (**6**- d_3). In addition, no deuterium incorporation into yatein (**11**) from (\pm)-[3- OC^2H_3]pluviatolides (**6**- d_3) and (\pm)-[3,4-(OC^2H_3) $_2$]burshehnerins (**9**- d_6) was observed. The mass spectra of yatein (**11**) obtained following administration of (**6**- d_3) and (**9**- d_6) did not show any extra ions in comparison with unlabelled authentic sample (Table 1).

Moreover, administration of (\pm)-[3- OC^2H_3]thujaplicatin (**3**- d_3) and (\pm)-[3,5-(OC^2H_3) $_2$]-5-methylthujaplicatin (**4**- d_6) in the small scale experiments did not lead to the formation of any of deuterium-labelled (**7**- d_3), (**8**- d_3 or d_6), and (**10**- d_3) (data not shown).

Simultaneous administration of two distinctly labelled lignans.

Simultaneous administration of (\pm)-[3- OC^2H_3]thujaplicatin (**3**- d_3) and (\pm)-[7,7- $^2\text{H}_2$, 3- OC^2H_3]secoisolariciresinols (**1**- d_3) gave both [$^2\text{H}_3$]yatein (**11**- d_3) (m/z 403, Table 1) and [$^2\text{H}_5$]yatein (**11**- d_5) (m/z 405, Table 1), whereas the administration of both (\pm)-[3- OC^2H_3]pluviatolides (**6**- d_3) and (\pm)-[7,7- $^2\text{H}_2$, 3- OC^2H_3]secoisolariciresinols (**1**- d_3) resulted in [$^2\text{H}_5$]yatein (**11**- d_5) (m/z 405, Table 1); the intensity of m/z 403 ion corresponding to [$^2\text{H}_3$]yatein (**11**- d_3) formation was insignificant (Table 1).

Discussion

We first examined the formation of the 5-methyl ether of the A-ring and the methylenedioxy bridge of the B-ring of yatein (**11**) (Fig. 1). When the deuterium-labelled dibenzylbutyrolactone lignans with 3,3',4,4',5-pentaalkoxy groups {(\pm)-[3- OC^2H_3]thujaplicatin (**3**- d_3), (\pm)-[3,5-(OC^2H_3) $_2$]-5-methylthujaplicatin (**4**- d_6), (\pm)-[3,5-(OC^2H_3) $_2$]-4,5-dimethylthujaplicatin (**5**- d_6), (\pm)-[3- OC^2H_3]-5-hydroxypluviatolides (**7**- d_3), (\pm)-[3,5-(OC^2H_3) $_2$]-4-demethylateins (**8**- d_6), and (\pm)-[3,4-(OC^2H_3) $_2$]-5-demethylateins (**10**- d_6) (Fig. 2)} were administered individually to *A. sylvestris* young shoots, all of them were found to be transformed to deuterium labelled [$^2\text{H}_3$] or [$^2\text{H}_5$]yatein (**11**- d_3 or **11**- d_6) (Tables 1–3). The results indicate that parallel pathways on the possible metabolic grid can operate in *A. sylvestris*, provided that these dibenzylbutyrolactone lignans are supplied to an appropriate reaction site of yatein biosynthesis in *A. sylvestris* cells. However this does not indicate all of these

dibenzylbutyrolactone lignans are physiologically significant endogenous precursors of yatein (**11**) in the species.

Thus, our attention was next focused on the physiological roles of the parallel conversions. First, feeding experiments with more upstream compounds were conducted. Phenylalanine is the entrance compound of phenylpropanoid biosynthesis and upon administration this compound is expected to move smoothly into a physiologically important pathway.²⁹ Hence we fed [$\text{ring-}^{13}\text{C}_6$]phenylalanine to *A. sylvestris*. GC-MS analysis indicated that ^{13}C was incorporated into matairesinol (**2**), 5-methylthujaplicatin (**4**), 4,5-dimethylthujaplicatin (**5**), pluviatolide (**6**), burshehnerin (**9**), and yatein (**11**) (Tables 1–3), but no evidence was obtained for the formation of ^{13}C -labelled [$^{13}\text{C}_{12}$] or [$^{13}\text{C}_6$]-5-hydroxypluviatolide (**7**- $^{13}\text{C}_{12}$ or $^{13}\text{C}_6$), [$^{13}\text{C}_{12}$] or [$^{13}\text{C}_6$]-4-demethylatein (**8**- $^{13}\text{C}_{12}$ or $^{13}\text{C}_6$), or [$^{13}\text{C}_{12}$] or [$^{13}\text{C}_6$]-5-demethylatein (**10**- $^{13}\text{C}_{12}$ or $^{13}\text{C}_6$) from [$\text{ring-}^{13}\text{C}_6$]phenylalanine (Fig. 5).

Second, (\pm)-[3- OC^2H_3]secoisolariciresinols (**1**- d_3) were administered, because secoisolariciresinol (**1**) is known to be converted to matairesinol (**2**) by the action of secoisolariciresinol dehydrogenase.^{29–33} This resulted in deuterium incorporation into matairesinol (**2**), thujaplicatin (**3**), 5-methylthujaplicatin (**4**), 4,5-dimethylthujaplicatin (**5**), pluviatolide (**6**), burshehnerin (**9**), and yatein (**11**) (Fig. 4 and Tables 1–3), but again no formation of deuterium-labelled (**7**- d_3), (**8**- d_3), or (**10**- d_3) was observed.

Third, in order to examine 5-hydroxylation step(s), the deuterium labelled dibenzylbutyrolactone lignans without the 5-hydroxy or 5-methoxy group were prepared. Administration of (\pm)-[3- OC^2H_3]matairesinols (**2**- d_3) resulted in deuterium incorporation into thujaplicatin (**3**) (Fig. 4) as well as pluviatolide (**6**) and burshehnerin (**9**) (Tables 1–3). In contrast, formation of deuterium-labelled 5-hydroxy- or 5-methoxy-lignans, (**7**- d_3), (**10**- d_3 or d_6), and (**8**- d_3), was not observed when (\pm)-[3- OC^2H_3]matairesinols (**2**- d_3), (\pm)-[3- OC^2H_3]pluviatolides (**6**- d_3), and (\pm)-[3,4-(OC^2H_3) $_2$]burshehnerins (**9**- d_6) were administered.

These results are in accord with the results of metabolic profiling, which detected the following lignans in the MeOH extracts of *A. sylvestris* young shoots: secoisolariciresinol (**1**), matairesinol (**2**), 5-methylthujaplicatin (**4**), 4,5-dimethylthujaplicatin (**5**), pluviatolide (**6**), burshehnerin (**9**), and yatein (**11**). In addition, the presence of endogenous, unlabelled thujaplicatin (**3**) was detected by mass chromatography (data not shown) and selected ion monitoring (Figs. 4-B and 4-C). However, no evidence indicating the presence of any of 5-hydroxypluviatolide (**7**), 4-demethylatein (**8**), and 5-demethylatein (**10**) was obtained (Fig. 5).

Thus, although 5-hydroxypluviatolide (**7**), 4-demethylatein (**8**), and 5-demethylatein (**10**) were converted to yatein (**11**) effectively under the experimental conditions employed, their conversion to yatein (**11**) is probably negligible in *de novo* lignan biosynthesis in *A. sylvestris*. This conclusion is based on the above mentioned facts summarized as follows: First, the upstream precursors, phenylalanine and secoisolariciresinol (**1**) were not transformed to any of (**7**), (**8**), and (**10**). Second, the lignans, (**7**), (**8**), and (**10**), could not be detected in the MeOH extracts from the plant. Third, conversion of pluviatolide (**6**), burshehnerin (**9**), thujaplicatin (**3**), and 5-methylthujaplicatin (**4**) into (**7**), (**8**), and (**10**) was not observed.

Taken together, these results indicate two independent branch metabolic pathways (solid arrows in Fig. 2) operating to affect the fate of matairesinol (**2**). One pathway leads to yatein (**11**) via thujaplicatin (**3**), 5-methylthujaplicatin (**4**), and 4,5-dimethylthujaplicatin (**5**); and the other gives burshehnerin (**9**) through pluviatolide (**6**). The involvement of 4-methylthujaplicatin (**12**) (Fig. 3), a regioisomer of 5-methylthujaplicatin (**4**), also seemed possible, but this is unlikely, because isotope incorporation into this lignan was not observed from any of labelled precursors tested (data not shown). The operation of two independent pathways was further reinforced




Fig. 5 Mass chromatograms of molecular ions and fragment ions formed after benzylic cleavages of A- and B-rings of 5-hydroxypluviatolide (7), 4-demethylyatein (8), and 5-demethylyatein (10) (TMS ether). *a*: unlabelled, synthesized authentic sample; *b*: the fraction corresponding to (7), (8), or (10) following administration of [ring- $^{13}\text{C}_6$]phenylalanine. M^+ : molecular ion of unlabelled, synthesized authentic sample; A^+ and B^+ : fragment ions formed after benzylic cleavages of A- and B-rings of unlabelled, synthesized authentic sample, respectively.




Fig. 6 Mass chromatograms of molecular ions and fragment ions formed after benzylic cleavages of A- and B-rings of 5-hydroxypluviatolide (7) (ethyl ether). *a*: unlabelled, synthesized authentic sample; *b*: the fraction corresponding to (7) following administration of (±)-[3- OC^2H_3]pluviatolides (6- d_3). M^+ : molecular ion of unlabelled, synthesized authentic sample; A^+ and B^+ : fragment ions formed after benzylic cleavages of A- and B-rings of unlabelled, synthesized authentic sample.

[3- OC^2H_3]pluviatolides (6- d_3) were transported to the lignan synthesis site under the conditions employed.

Kawai *et al.* administrated [7,7- $^2\text{H}_2$, 3- OC^2H_3]matairesinol (2- d_3) to *Thuja occidentalis* shoots, and detected deuterium incorporation into thujaplicatin (3), which indicates that the conversion of matairesinol (2) to thujaplicatin (3) is not specific to *A. sylvestris*, but also occurs in another species, *T. occidentalis*.³⁴

Recently, we have detected pinoresinol/lariciresinol reductase (PLR) activity in *A. sylvestris*,²⁶ catalyzing the reduction of pinoresinol to secoisolariciresinol (1) via lariciresinol (Fig. 2). This suggests the intermediacy of pinoresinol and lariciresinol in lignan biosynthesis in this species. Taken together, we propose a possible biosynthetic pathway of yatein (11) from coniferyl alcohol, concomitant with a branch leading to bursehernin (9) from matairesinol (2) (Fig. 2).

The biosynthetic pathway for yatein (11) in *Anthriscus sylvestris* (Fig. 2) is in line with the previous reports outlined in Fig. 1. However, the pathway differs from two other recently proposed pathways in relation to the biosynthesis of podophyllotoxin derivatives in *Linum* spp.^{35,36} One of these proposed pathways had the intact incorporation of 3,4-methylenedioxybenzoic acid into podophyllotoxin,³⁵ and the other had the benzylic hydroxylation occurring at an earlier stage (C7' of matairesinol was hydroxylated to afford 7'-hydroxymatairesinol, which was then metabolized to 5-methoxy-podophyllotoxin³⁶).

In conclusion, the biosynthetic pathway from matairesinol (2) to yatein (11) has been presented for the first time based on concrete experimental evidence. The pathway involves 5-hydroxylation of matairesinol (2) to give thujaplicatin (3),

followed by dual methylation and finally 3',4'-methylenedioxy bridge formation to afford yatein (11). Additionally, the conversion of matairesinol (2) to bursehernin (9) was also found to occur, but does not lead to yatein (11).

Experimental

Plant materials

Anthriscus sylvestris Hoffm. (Umbelliferae) plants were collected in October 2001 at Kyoto University Forest in Ashiu, Kyoto. The plants were maintained in the experimental garden of Wood Research Institute, Kyoto University.


Instrumentation

^1H NMR and ^{13}C NMR spectra were taken with a JAM-LA400MK FT NMR System (JEOL). Chemical shifts and coupling constants (J) were given in δ and Hz, respectively. GC-MS was performed on a JMS-DX303HF mass spectrometer (JEOL) equipped with a Hewlett-Packard 5890J gas chromatograph and a JMA-DA5000 mass data system. GC-MS measurement conditions were as follows: electron-impact mode, 70 eV; gas-chromatographic column, Shimadzu HiCup CBP-10 M25-025 (5 m \times 0.2 mm); temperature, 40 $^\circ\text{C}$ at $t = 0$ –2 min, then to 230 $^\circ\text{C}$ at 30 $^\circ\text{C min}^{-1}$; carrier gas, He; splitless injection. Samples dissolved in *N,O*-bis(trimethylsilyl)acetamide were subjected to GC-MS measurement after heating at 60 $^\circ\text{C}$ for 45 min.

Synthesis of lignans and chemicals

Synthesis of benzyl- γ -butyrolactones. (±)-3-(4-Benzyloxy-3-methoxybenzyl)- γ -butyrolactones (13a) and (±)-3-(3,4-methylenedioxybenzyl)- γ -butyrolactones (13c) were prepared exactly as previously described^{30,40} (13a): δ_{H} (CDCl_3) 7.24–7.44 (5 H, m), 6.81 (1 H, d, J 8.0), 6.67 (1 H, d, J 2.0), 6.61 (1 H, dd, J 8.2 and 1.8), 5.12 (2 H, s), 4.32 (1 H, dd, J 9.1 and 7.0), 4.02 (1 H, dd, J 9.3 and 6.1), 3.87 (3 H, s), 2.75–2.86 (1 H, m), 2.67–2.72 (2 H, m), 2.59 (1 H, dd, J 17.6 and 8.1), 2.27 (1 H, dd, J 17.4 and 7.0). (13c): δ_{H} (CDCl_3) 6.74 (1 H, d, J 7.8), 6.63 (1 H, s), 6.59 (1 H, d, J 7.8), 5.94 (2 H, s), 4.32 (1 H, dd, J 7.3 and 6.8), 4.01 (1 H, dd, J 9.3 and 6.1), 2.74–2.84 (1 H, m), 2.66–2.72 (2 H, m), 2.59 (1 H, dd, J 17.6 and 8.0), 2.26 (1 H, dd, J 17.3 and 6.8).

(±)-3-(4-*tert*-Butyldimethylsilyloxy-3-methoxybenzyl)- γ -butyrolactones (13b) were prepared by catalytic (Pd-C) hydrogenation of (13a) followed by *tert*-butyldimethylsilylation (*tert*-butyldimethylsilyl chloride, imidazole, DMF, rt) (13b): δ_{H} (CDCl_3) 6.77 (1 H, d, J 8.0), 6.61 (1 H, d, J 2.0), 6.58 (1 H, dd, J 7.8 and 1.9), 4.31 (1 H, dd, J 9.0 and 7.1), 4.02 (1 H, dd, J 9.1 and 6.2), 3.78 (3 H, s), 2.76–2.86 (1 H, m), 2.66–2.72 (2 H, m), 2.56 (1 H, dd, J 17.4 and 8.2), 2.27 (1 H, dd, J 17.4 and 7.0), 0.98 (9 H, s), 0.13 (6 H, s).



Scheme 1 Synthetic routes for deuterium-labelled benzyl bromide derivatives (**14a–14h**). *Reagents and conditions*: i, NaBH₄, MeOH, rt, 10 min; ii, PBr₃, Et₂O, rt, 1 h; iii, c. HCl, AcOH, reflux, 1 h; iv, I₂, KI, NaOH (aq), rt, 2 h; v, NaOH (aq), CuSO₄, 125 °C, 6 h; vi, BnBr, K₂CO₃, DMF, 70 °C, 4 h; vii, C²H₅O²H, Na, 128 °C, 3 h; viii, C²H₅I, K₂CO₃, DMF, rt, 2 h; ix, CH(OMe)₃, *p*-TsOH, MeOH, 0 °C, 10 min; x, O₂, BuLi, Et₂O, –35 °C, 40 min; xi, 1 M HCl, acetone, 0 °C, 5 min; xii, KMnO₄, acetone, rt, 1 h; xiii, CH₃CHN₂, Et₂O, 0 °C, 3 min; xiv, LiAlH₄, Et₂O, –35 °C, 40 min.

Synthesis of benzyl bromides. Unlabelled and deuterium-labelled benzyl bromides (**14a–14h**) were synthesized from the vanillin derivatives [vanillin (**14j**), syringaldehyde (**14r**), 3,4-dimethoxy-5-hydroxybenzaldehyde (**14y**) (Aldrich), and [3-OC²H₃]benzylvanillin (**14i**)³⁰], respectively, by the methods described previously,^{30,40–43} which are outlined in Scheme 1.

4,5-Dibenzyloxy-3-methoxybenzyl bromide (**14a**): $\delta_{\text{H}}(\text{CDCl}_3)$ 7.24–7.50 (10 H, m), 6.68 (1 H, d, *J* 2.0), 6.63 (1 H, d, *J* 2.0), 5.10 (2 H, s), 5.03 (2 H, s), 4.44 (2 H, s), 3.85 (3 H, s).

4-Benzyloxy-3,5-dimethoxybenzyl bromide (**14b**): $\delta_{\text{H}}(\text{CDCl}_3)$ 7.23–7.52 (5 H, m), 6.60 (2 H, s), 4.99 (2 H, s), 4.42 (2 H, s), 3.83 (6 H, s).

5-Benzyloxy-3,4-dimethoxybenzyl bromide (**14c**): $\delta_{\text{H}}(\text{CDCl}_3)$ 7.17–7.42 (5 H, m), 6.60 (1 H, d, *J* 1.9), 6.56 (1 H, d, *J* 2.0), 5.02 (2 H, s), 4.35 (2 H, s), 3.80 (3 H, s), 3.80 (3 H, s).

[3-OC²H₃]-4-Benzyloxy-3-methoxybenzyl bromide (**14d**): $\delta_{\text{H}}(\text{CDCl}_3)$ 7.24–7.46 (5 H, m), 6.92 (1 H, d, *J* 1.9), 6.87 (1 H, dd, *J* 8.3 and 2.0), 6.81 (1 H, d, *J* 8.0), 5.15 (2 H, s), 4.48 (2 H, s).

[3-OC²H₃]-4,5-Dibenzyloxy-3-methoxybenzyl bromide (**14e**): $\delta_{\text{H}}(\text{CDCl}_3)$ 7.24–7.47 (10 H, m), 6.68 (1 H, d, *J* 2.0), 6.63 (1 H, d, *J* 2.0), 5.09 (2 H, s), 5.02 (2 H, s), 4.44 (2 H, s).

[3,5-(OC²H₃)₂]-4-Benzyloxy-3,5-dimethoxybenzyl bromide (**14f**): $\delta_{\text{H}}(\text{CDCl}_3)$ 7.24–7.50 (5 H, m), 6.59 (2 H, s), 4.99 (2 H, s), 4.45 (2 H, s).

[3,4-(OC²H₃)₂]-5-Benzyloxy-3,4-dimethoxybenzyl bromide (**14g**): $\delta_{\text{H}}(\text{CDCl}_3)$ 7.16–7.47 (5 H, m), 6.59 (1 H, s), 6.55 (1 H, s), 5.06 (2 H, s), 4.36 (2 H, s).


[α,α -²H₂, 3-OC²H₃]-4-Benzyloxy-3-methoxybenzyl bromide (**14h**): $\delta_{\text{H}}(\text{CDCl}_3)$ 7.21–7.40 (5 H, m), 6.87 (1 H, d, *J* 2.2), 6.82 (1 H, dd, *J* 8.2 and 2.1), 6.74 (1 H, d, *J* 8.1), 5.09 (2 H, s).

Synthesis of dibenzylbutyrolactone lignans. (\pm)-Matairesinols (**2**),³⁷ (\pm)-pluviatolides (**6**),³⁸ and (\pm)-bursehernins (**9**)³⁹ were prepared previously.

The dibenzylbutyrolactone lignans, (\pm)-[3-OC²H₃]matairesinols (**2-d**₃), (\pm)-[7,7-²H₂, 3-OC²H₃]matairesinols (**2-d**₅), (\pm)-thujaplicatins (**3**), (\pm)-[3-OC²H₃]thujaplicatins (**3-d**₃), (\pm)-5-methylthujaplicatins (**4**), (\pm)-[3,5-(OC²H₃)₂]-5-methylthujaplicatins (**4-d**₆), (\pm)-[3-OC²H₃]pluviatolides (**6-d**₃), (\pm)-5-hydroxypluviatolides (**7**), (\pm)-[3-OC²H₃]-5-hydroxypluviatolides (**7-d**₃), (\pm)-4-demethyleateins (**8**), (\pm)-[3,5-(OC²H₃)₂]-4-demethyleateins (**8-d**₆), (\pm)-5-demethyleateins (**10**), (\pm)-[3,4-(OC²H₃)₂]-5-demethyleateins (**10-d**₆), and (\pm)-4-methylthujaplicatins (**12**)

were prepared by lithium hexamethyldisilylamide-catalyzed condensation of appropriate combinations of γ -butyrolactones (**13a–13c**) and benzyl bromides (**14a–14h**) followed by deprotection as previously reported,^{30,40–43} which is outlined in Scheme 2.

(\pm)-[3-OC²H₃]matairesinols (**2-d**₃): $\delta_{\text{H}}(\text{CDCl}_3)$ 6.80 (1 H, d, *J* 8.6), 6.78 (1 H, d, *J* 7.8), 6.56–6.62 (2 H, m), 6.50 (1 H, d, *J* 8.0), 6.34 (1 H, s), 4.13 (1 H, dd, *J* 8.6 and 7.6), 3.90 (1 H, dd, *J* 8.8 and 8.8), 3.80 (3 H, s), 2.94 (1 H, dd, *J* 13.7 and 4.9), 2.87 (1 H, dd, *J* 13.7 and 7.3), 2.40–2.64 (4 H, m); *m/z* (EI) 361.1578



Scheme 2 Synthetic routes for unlabelled and deuterium-labelled lignans. *Reagents and conditions*: i, Lithium hexamethyldisilylamide, HMPA, THF, –35 °C, 45 min; ii, 10% Pd-C, H₂, THF, MeOH, rt, 1 h; iii, LiAlH₄, Et₂O, –35 °C, 40 min; iv, CH₃I, K₂CO₃, DMF, rt, 2 h; v, *n*-Bu₄NF, THF, 0 °C, 20 min; vi, C²H₅I, K₂CO₃, DMF, rt, 2 h; vii, CH₃CHN₂, Et₂O, rt, 10 h.

(M⁺, 42.8%. C₂₀H₁₉²H₃O₆ requires 361.1604), 360 (1.1), 359 (1.1), 358 (0.5), 149 (10.5), 140 (100), 137 (42.1), 131 (12.4), 122 (12.5).

(±)-[7,7-²H₂, 3-OC²H₃]Matairesinols (**2-d₃**): δ_H (CDCl₃) 6.70–6.79 (2 H, m), 6.50–6.57 (2 H, m), 6.44 (1 H, dd, *J* 6.4 and 2.0), 6.34 (1 H, d, *J* 2.0), 5.45 (2 H, d, *J* 8.6), 4.08 (1 H, dd, *J* 9.2 and 7.2), 3.82 (1 H, dd, *J* 8.3 and 8.0), 3.74 (3 H, s), 2.58–2.35 (4 H, m); *m/z* (EI) 363.1734 (M⁺, 48.2%. C₂₀H₁₇²H₅O₆ requires 363.1730), 362 (3.5), 361 (1.5), 360 (0.6), 359 (0.2), 358 (0.0), 149 (11.5), 142 (100), 137 (47.5), 131 (10.9), 122 (7.8).

(±)-Thujaplicatins (**3**): δ_H(CDCl₃) 6.72 (1 H, d, *J* 8.1), 6.44 (1 H, dd, *J* 7.9 and 1.8), 6.38 (1 H, d, *J* 1.7), 6.30 (1 H, d, *J* 2.0), 6.17 (1 H, d, *J* 2.0), 4.09 (1 H, dd, *J* 9.1 and 6.9), 3.82 (1 H, dd, *J* 9.1 and 6.9), 3.76 (3 H, s), 3.73 (3 H, s), 2.85 (1 H, dd, *J* 13.9 and 4.9), 2.75 (1 H, dd, *J* 14.0 and 6.9), 2.36–2.58 (4 H, m); *m/z* (EI) 374.1380 (M⁺, 73.9%. C₂₀H₂₂O₇ requires 374.1366), 237 (15.0), 223 (9.7), 163 (11.9), 153 (100), 137 (92.8), 131 (24.7), 122 (20.3).

(±)-[3-OC²H₃]Thujaplicatins (**3-d₃**): δ_H(CDCl₃) 6.78 (1 H, d, *J* 7.8), 6.50 (1 H, dd, *J* 8.0 and 2.0), 6.44 (1 H, d, *J* 1.7), 6.36 (1 H, d, *J* 2.0), 6.23 (1 H, d, *J* 1.7), 4.15 (1 H, dd, *J* 9.2 and 7.0), 3.88 (1 H, dd, *J* 9.2 and 7.2), 3.82 (3 H, s), 2.92 (1 H, dd, *J* 14.0 and 5.0), 2.81 (1 H, dd, *J* 14.0 and 6.9), 2.42–2.64 (4 H, m); *m/z* (EI) 377.1557 (M⁺, 76.8%. C₂₀H₁₉²H₃O₇ requires 377.1554), 376 (4.1), 375 (4.1), 374 (1.4), 240 (14.2), 226 (10.6), 163 (14.1), 156 (100), 137 (98.5), 131 (25.8), 122 (20.5).

(±)-5-Methylthujaplicatins (**4**): δ_H(CDCl₃) 6.75 (1 H, d, *J* 7.8), 6.45 (1 H, dd, *J* 7.9 and 1.8), 6.34 (1 H, d, *J* 1.7), 6.25 (2 H, s), 4.11 (1 H, dd, *J* 9.0 and 7.3), 3.82 (1 H, dd, *J* 9.2 and 7.4), 3.76 (6 H, s), 3.73 (3 H, s), 2.86 (1 H, dd, *J* 13.8 and 5.4), 2.80 (1 H, dd, *J* 13.9 and 6.6), 2.33–2.60 (4 H, m); *m/z* (EI) 388.1512 (M⁺, 73.5%. C₂₁H₂₄O₇ requires 388.1522), 173 (11.7), 167 (100), 149 (13.7), 137 (46.1), 131 (9.9), 122 (11.9).

(±)-[3,5-(OC²H₃)₂]-5-Methylthujaplicatins (**4-d₆**): δ_H(CDCl₃) 6.79 (1 H, d, *J* 8.0), 6.51 (1 H, dd, *J* 8.1 and 1.9), 6.40 (1 H, d, *J* 1.9), 6.30 (2 H, s), 4.17 (1 H, dd, *J* 9.1 and 7.2), 3.88 (1 H, dd, *J* 9.1 and 7.4), 3.79 (3 H, s), 2.92 (1 H, dd, *J* 14.2 and 5.4), 2.87 (1 H, dd, *J* 14.2 and 6.8), 2.40–2.65 (4 H, m); *m/z* (EI) 394.1897 (M⁺, 57.9%. C₂₁H₁₈²H₆O₇ requires 394.1898), 393 (0.0), 392 (2.3), 391 (0.8), 390 (0.6), 389 (0.4), 388 (0.0), 173 (100), 149 (4.0), 137 (35.1), 131 (10.6), 122 (6.8).

(±)-[3-OC²H₃]Pluviatolides (**6-d₃**): δ_H (CDCl₃) 6.76 (1 H, d, *J* 8.1), 6.52–6.65 (3 H, m), 6.34–6.42 (2 H, m), 5.83–5.87 (2 H, m), 4.03 (1 H, dd, *J* 9.0 and 7.1), 3.77 (1 H, dd, *J* 10.4 and 7.1), 2.88 (1 H, dd, *J* 14.1 and 5.1), 2.80 (1 H, dd, *J* 14.2 and 6.8), 2.23–2.56 (4 H, m); *m/z* (EI) 359.1429 (M⁺, 42.2%. C₂₀H₁₇²H₃O₆ requires 359.1448), 358 (2.6), 357 (1.5), 356 (0.6), 223 (11.4), 162 (10.1), 140 (100), 135 (38.2), 131 (9.5), 122 (9.6).

(±)-5-Hydroxypluviatolides (**7**): δ_H (CDCl₃) 6.68 (1 H, d, *J* 8.3), 6.45 (1 H, m), 6.44 (1 H, s), 6.37 (1 H, d, *J* 1.7), 6.26 (1 H, d, *J* 1.4), 5.83–5.87 (2 H, m), 4.11 (1 H, dd, *J* 9.3 and 7.3), 3.84 (1 H, dd, *J* 9.0 and 6.8), 3.81 (3 H, s), 2.91 (1 H, dd, *J* 13.9 and 4.9), 2.80 (1 H, dd, *J* 13.9 and 6.8), 2.40–2.63 (4 H, m); *m/z* (EI) 372.1205 (M⁺, 89.5%. C₂₀H₂₀O₇ requires 372.1209), 236 (31.4), 191 (16.3), 161 (16.7), 153 (100), 149 (15.8), 135 (86.1), 131 (34.0), 122 (13.0).

(±)-[3-OC²H₃]-5-Hydroxypluviatolides (**7-d₃**): δ_H (CDCl₃) 6.68 (1 H, d, *J* 8.3), 6.44–6.48 (1 H, m), 6.45 (1 H, s), 6.37 (1 H, d, *J* 1.7), 6.27 (1 H, d, *J* 1.7), 5.91–5.94 (2 H, m), 4.11 (1 H, dd, *J* 9.3 and 6.8), 3.85 (1 H, dd, *J* 9.2 and 7.0), 2.92 (1 H, dd, *J* 14.0 and 5.0), 2.81 (1 H, dd, *J* 13.9 and 6.8), 2.42–2.64 (4 H, m); *m/z* (EI) 375.1375 (M⁺, 89.1%. C₂₀H₁₇²H₃O₇ requires 375.1397), 374 (5.7), 373 (7.3), 372 (2.5), 239 (28.8), 194 (13.9), 161 (19.0), 156 (100), 149 (34.0), 135 (73.1), 173 (23.1), 122 (11.3).

(±)-4-Demethylateins (**8**): δ_H (CDCl₃) 6.69 (1 H, d, *J* 7.6), 6.43–6.48 (2 H, m), 6.35 (2 H, s), 5.92–5.93 (2 H, m), 4.15 (1 H, dd, *J* 9.3 and 7.3), about 3.87 (1 H), 3.85 (6 H, s), 2.89 (2 H, d, *J* 6.1), 2.42–2.64 (4 H, m); *m/z* (EI) 386.1362 (M⁺, 55.3%. C₂₁H₂₂O₇ requires 386.1366), 250 (13.8), 167 (100), 161 (8.8), 135 (32.7), 131 (8.9).

(±)-[3,5-(OC²H₃)₂]-4-Demethylateins (**8-d₆**): δ_H (CDCl₃) 6.69 (1 H, d, *J* 7.8), 6.46 (1 H, d, *J* 7.6), 6.45 (1 H, s), 6.34 (2 H, s), 5.92–5.93 (2 H, m), 4.13 (1 H, dd, *J* 9.5 and 7.6), 3.86 (1 H, dd, *J* 9.0 and 7.6), 2.89 (2 H, d, *J* 6.1), 2.43–2.65 (4 H, m); *m/z* (EI) 392.1735 (M⁺, 57.9%. C₂₁H₁₆²H₆O₇ requires 392.1742), 391 (0.0), 390 (2.4), 389 (1.0), 388 (0.5), 387 (0.7), 386 (0.8), 256 (15.9), 173 (100), 161 (6.6), 149 (18.8), 135 (32.0), 131 (9.8).

(±)-5-Demethylateins (**10**): δ_H (CDCl₃) 6.62 (1 H, d, *J* 8.3), 6.37–6.42 (2 H, m), 6.32 (1 H, d, *J* 2.0), 6.21 (1 H, d, *J* 1.7), 5.83–5.87 (2 H, m), 4.07 (1 H, dd, *J* 9.3 and 6.8), about 3.79 (1 H), 3.79 (3 H, s), 3.79 (3 H, s), 2.88 (1 H, dd, *J* 13.9 and 4.9), 2.73 (1 H, dd, *J* 13.9 and 7.1), 2.35–2.57 (4 H, m); *m/z* (EI) 386.1382 (M⁺, 90.3%. C₂₁H₂₂O₇ requires 386.1365), 250 (24.8), 237 (12.9), 205 (14.6), 167 (100), 161 (16.9), 135 (70.8), 131 (18.3).

(±)-[3,4-(OC²H₃)₂]-5-Demethylateins (**10-d₆**): δ_H (CDCl₃) 6.68 (1 H, d, *J* 8.3), 6.43–6.49 (2 H, m), 6.38 (1 H, d, *J* 2.0), 6.26 (1 H, d, *J* 1.7), 5.87–5.93 (2 H, m), 4.13 (1 H, dd, *J* 9.3 and 6.6), 3.85 (1 H, dd, *J* 9.3 and 7.0), 2.94 (1 H, dd, *J* 14.0 and 4.8), 2.80 (1 H, dd, *J* 13.9 and 7.1), 2.46–2.65 (4 H, m); *m/z* (EI) 392.1740 (M⁺, 75.1%. C₂₁H₁₆²H₆O₇ requires 392.1742), 391 (0.0), 390 (2.3), 389 (1.4), 388 (1.1), 387 (0.0), 386 (0.0), 256 (30.2), 243 (15.3), 211 (14.6), 173 (100), 161 (12.6), 135 (56.0), 131 (17.5).

(±)-4-Methylthujaplicatins (**12**): δ_H(CDCl₃) 6.79 (1 H, d, *J* 8.0), 6.50 (1 H, dd, *J* 8.1 and 1.9), 6.47 (1 H, d, *J* 2.0), 6.37 (1 H, d, *J* 2.0), 6.27 (1 H, d, *J* 1.9), 4.14 (1 H, dd, *J* 9.0 and 6.8), about 3.87 (1 H), 3.86 (3 H, s), 3.83 (3 H, s), 3.79 (3 H, s), 2.92 (1 H, dd, *J* 13.9 and 5.1), 2.83 (1 H, dd, *J* 13.9 and 6.8), 2.44–2.64 (4 H, m); *m/z* (EI) 388.1503 (M⁺, 92.3%. C₂₁H₂₄O₇ requires 388.1522), 167 (100), 149 (39.7), 137 (55.8), 131 (27.2), 122 (20.3).

(±)-4,5-Dimethylthujaplicatins (**5**): δ_H (CDCl₃) 6.74 (1 H, d, *J* 8.0), 6.45 (1 H, dd, *J* 8.1 and 1.7), 6.37 (1 H, d, *J* 1.7), 6.26 (2 H, s), 4.12 (1 H, dd, *J* 9.0 and 7.3), 3.83 (1 H, dd, *J* 8.8 and 8.0), 3.75 (3 H, s), 3.74 (3 H, s), 3.74 (6 H, s), 2.88 (1 H, dd, *J* 13.9 and 5.4), 2.83 (1 H, dd, *J* 14.2 and 6.6), 2.36–2.62 (4 H, m); *m/z* (EI) 402.1696 (M⁺, 100%. C₂₂H₂₆O₇ requires 402.1679), 251 (13.4), 181 (92.9), 137 (45.0), 131 (11.3), 122 (11.5).

(±)-[3,5-(OC²H₃)₂]-4,5-Dimethylthujaplicatins (**5-d₆**): δ_H (CDCl₃) 6.80 (1 H, d, *J* 8.0), 6.52 (1 H, dd, *J* 8.0 and 2.0), 6.43 (1 H, d, *J* 2.0), 6.32 (2 H, s), 4.18 (1 H, dd, *J* 9.2 and 7.2), 3.88 (1 H, dd, *J* 9.0 and 7.6), 3.81 (3 H, s), 3.80 (3 H, s), 2.94 (1 H, dd, *J* 13.9 and 5.4), 2.88 (1 H, dd, *J* 14.2 and 6.6), 2.42–2.67 (4 H, m); *m/z* (EI) 408.2037 (M⁺, 75.1%. C₂₂H₂₀²H₆O₇ requires 408.2055), 407 (0.0), 406 (0.0), 405 (0.0), 404 (0.0), 403 (0.8), 402 (0.0), 257 (8.0), 187 (100), 137 (35.5), 131 (10.2), 122 (6.0).

(±)-[3,4-(OC²H₃)₂]Bursehernins (**9-d₃**): δ_H(CDCl₃) 6.76 (1 H, d, *J* 8.1), 6.62–6.78 (3 H, m), 6.44 (1 H, d, *J* 8.1), 6.42 (1 H, s), 5.91–5.95 (2 H, m), 4.10 (1 H, dd, *J* 9.2 and 6.7), 3.84 (1 H, dd, *J* 9.0 and 7.1), 2.95 (1 H, dd, *J* 14.0 and 5.1), 2.87 (1 H, dd, *J* 14.0 and 7.0), 2.40–2.70 (4 H, m); *m/z* (EI) 376.1779 (M⁺, 47.1%. C₂₁H₁₆²H₆O₆ requires 376.1793), 375 (0.0), 374 (1.3), 373 (0.4), 372 (0.7), 371 (0.0), 370 (0.0), 240 (13.2), 214 (5.4), 161 (5.6), 157 (100), 135 (22.4).

(±)-Yateins (**11**): δ_H(CDCl₃) 6.68 (1 H, d, *J* 8.0), 6.45 (1 H, d, *J* 8.1), 6.44 (1 H, s), 6.34 (2 H, s), 5.90–5.94 (2 H, m), 4.16 (1 H, dd, *J* 9.1 and 7.2), 3.86 (1 H, dd, *J* 9.0 and 5.6), 3.81 (3 H, s), 3.81 (6 H, s), 2.92 (1 H, dd, *J* 14.2 and 5.4), 2.87 (1 H, dd, *J* 13.9 and 6.4), 2.40–2.66 (4 H, m); *m/z* (EI) 400.1509 (M⁺, 76.4%. C₂₂H₂₄O₇ requires 400.1522), 251 (11.2), 181 (100), 167 (10.5), 149 (12.4), 135 (28.6).

(±)-4,5-Diethyl-5-hydroxypluviatolides (**4,5-DiEt-7**): δ_H (CDCl₃) 6.62 (1 H, d, *J* 8.5), 6.36–6.42 (2 H, m), 6.28 (1 H, d, *J* 2.0), 6.27 (1 H, d, *J* 2.0), 5.85–5.88 (2 H, m), 4.08 (1 H, dd, *J* 9.2 and 7.2), 3.96 (2 H, q, *J* 7.1), 3.95 (2 H, q, *J* 7.1), 3.80 (1 H, dd, *J* 9.2 and 7.3), 3.74 (3 H, s), 2.87 (1 H, dd, *J* 13.9 and 5.1), 2.79 (1 H, dd, *J* 14.0 and 7.0), 2.46–2.58 (4 H, m), 1.35 (3 H, t, *J* 7.0), 1.27 (3 H, t, *J* 7.1); *m/z* (EI) 428.1833 (M⁺, 100%. C₂₄H₂₈O₇ requires 428.1835), 399 (12.0), 210 (33.9), 181 (38.6), 153 (30.6), 135 (59.4).

(±)-4-Ethyl-4-demethyleateins (4-Et-**8**): δ_{H} (CDCl₃) 6.62 (1 H, d, *J* 8.3), 6.36–6.42 (2 H, m), 6.29 (2 H, s), 5.85–5.87 (2 H, m), 4.09 (1 H, dd, *J* 9.1 and 6.9), 3.95 (2 H, q, *J* 7.1), 3.80 (1 H, dd, *J* 9.3 and 7.6), 3.74 (6 H, s), 2.88 (1 H, dd, *J* 13.9 and 5.2), 2.80 (1 H, dd, *J* 13.9 and 6.8), 2.35–2.60 (4 H, m), 1.27 (3 H, t, *J* 7.1); *m/z* (EI) 414.1660 (M⁺, 100%). C₂₃H₂₆O₇ requires 414.1678), 385 (16.8), 278 (7.1), 217 (6.2), 195 (34.8), 167 (86.5), 135 (66.0), 131 (10.5).

(±)-[3,4-(OC²H₃)₂]-5-Ethyl-5-demethyleateins (5-Et-**10-d₆**): δ_{H} (CDCl₃) 6.63 (1 H, d, *J* 8.3), 6.37–6.43 (2 H, m), 6.28 (1 H, d, *J* 2.0), 6.26 (1 H, d, *J* 2.0), 5.85–5.88 (2 H, m), 4.09 (1 H, dd, *J* 9.1 and 7.2), 3.97 (2 H, q, *J* 7.0), 3.80 (1 H, dd, *J* 9.0 and 7.6), 2.85 (1 H, dd, *J* 13.9 and 5.1), 2.80 (1 H, dd, *J* 13.9 and 6.3), 2.36–2.65 (4 H, m), 1.36 (3 H, t, *J* 7.1); *m/z* (EI) 420.2047 (M⁺, 100%). C₂₃H₂₀²H₆O₇ requires 420.2055), 419 (0.0), 418 (0.0), 417 (0.0), 416 (1.0), 415 (1.0), 414 (0.0), 284 (12.3), 201 (92.0), 173 (30.9), 135 (46.9) 131 (12.4).

Synthesis of dibenzylbutane lignans. (±)-[3-OC²H₃]Secoisolariciresinols (**1-d₃**) and (±)-[7,7-²H₂, 3-OC²H₃]secoisolariciresinols (**1-d₅**) were prepared by reduction of (±)-[3-OC²H₃]matairesinols (**2-d₃**) and (±)-[7,7-²H₂, 3-OC²H₃]matairesinols (**2-d₅**), respectively, as previously.⁴⁴ (**1-d₃**): δ_{H} (CDCl₃) 6.79 (2 H, d, *J* 7.8), 6.55–6.65 (4 H, m), about 3.82 (2 H), 3.80 (3 H, s), 3.54 (2 H, dd, *J* 11.3 and 4.3), 2.73 (2 H, dd, *J* 13.7 and 8.1), 2.63 (2 H, dd, *J* 13.7 and 6.2), 1.85 (2 H, m); *m/z* (EI) 365.1935 (M⁺, 18.0%). C₂₀H₂₃²H₃O₆ requires 365.1917), 364 (2.9), 353 (3.3), 362 (2.7), 347 (11.8), 192 (8.6), 189 (9.2), 140 (100), 137 (98.7), 122 (19.4). (**1-d₅**): δ_{H} (CDCl₃) 6.73 (2 H, d, *J* 8.0), 6.50–6.58 (4 H, m), about 3.75 (2 H), 3.74 (3 H, s), 3.48 (2 H, dd, *J* 11.5 and 4.4), 2.67 (1 H, dd, *J* 13.8 and 8.2), 2.57 (1 H, dd, *J* 13.8 and 6.7), 1.78 (2 H, m); *m/z* (EI) 367.2031 (M⁺, 27.1%). C₂₀H₂₁²H₅O₆ requires 367.2043), 366 (3.6), 365 (6.1), 364 (3.1), 363 (8.7), 362 (1.3), 349 (14.8), 194 (7.6), 189 (6.8), 142 (99.2), 137 (100), 122 (11.2).

Chemicals

L-[ring-¹³C₆]phenylalanine (99 atom % ¹³C), C²H₃I (99.5 atom % ²H), and LiAlH₄ (98 atom % ²H) were purchased from ICON, Aldrich, and Aldrich, respectively. All chemicals used were reagent grade unless otherwise stated.

Lignans in *Anthriscus sylvestris*

Young shoots of *Anthriscus sylvestris* were harvested and washed sequentially with tap and distilled water. The plant materials thus obtained (2.4 g) were frozen (liquid N₂), freeze-dried, disintegrated with scissors, and then extracted with hot MeOH (16 ml). The MeOH extract was treated with β -glucosidase (from almonds, SIGMA G-0395, 68 units in 5.0 ml of NaOAc buffer at pH 5.0) for 24 h at 37 °C. The reaction mixture was extracted with AcOEt (3.0 ml \times 3), and the solvent was evaporated off. The AcOEt extracts (16.3 mg) thus obtained were submitted to TLC separation (solvents: appropriate mixtures of AcOEt–CHCl₃) to afford 3 fractions. An aliquot of each fraction was subjected to GC-MS analysis after heating with 14 μ l of *N,O*-bis(trimethylsilyl)acetamide (BSA) for 45 min at 60 °C⁴⁴ so that lignans present in the fractions were identified. In a separate experiment, freeze-dried, aerial parts (including leaves, petioles and racemes) of *A. sylvestris* (39.8 g) were pulverized and extracted with hot MeOH as above but scaled up proportionately. The MeOH extract (17.3 g) thus obtained was treated with β -glucosidase and the reaction products were extracted with AcOEt. The AcOEt extract (1.2 g) was subjected to repeated silica gel column and thin layer chromatography to afford pure yatein (**11**) (90.2 mg) and deoxypodophyllotoxin (17.9 mg).

Feeding experiments

Administration of lignans to *Anthriscus sylvestris*: deuterium labelled lignans (0.4 mg each), (±)-[3-OC²H₃]matairesinols (**2-d₃**), (±)-[3-OC²H₃]thujaplicatins (**3-d₃**), (±)-[3,5-(OC²H₃)₂]-5-methylthujaplicatins (**4-d₆**), (±)-[3,5-(OC²H₃)₂]-4,5-dimethylthujaplicatins (**5-d₆**), (±)-[3-OC²H₃]pluviatolides (**6-d₃**), (±)-[3-OC²H₃]-5-hydroxypluviatolides (**7-d₃**), (±)-[3,5-(OC²H₃)₂]-4-demethyleateins (**8-d₆**), (±)-[3,4-(OC²H₃)₂]burshehnins (**9-d₆**), and (±)-[3,4-(OC²H₃)₂]-5-demethyleateins (**10-d₆**), were dissolved individually in MeOH or DMSO (62 μ l) and dispersed in distilled water (438 μ l). Young shoots (about 3 cm long) of *A. sylvestris* were cut by means of scissors, and the cut end of each shoot was placed directly in each solution of the deuterium labelled compounds. Following uptake, each shoot was metabolized for 3 d and freeze-dried. The resulting dried material was hand-disintegrated using scissors and extracted with hot MeOH. The MeOH extract was treated with β -glucosidase and was submitted to trimethylsilylation followed by GC-MS analysis. The peaks on GC corresponding to the lignans (**1**) (*t_R* = 10.6 min), (**2**) (*t_R* = 15.3 min), (**3**) (*t_R* = 17.5 min), (**4**) (*t_R* = 18.4 min), (**5**) (*t_R* = 18.9 min), (**6**) (*t_R* = 14.6 min), (**7**) (*t_R* = 16.6 min), (**8**) (*t_R* = 17.4 min), (**9**) (*t_R* = 15.2 min), (**10**) (*t_R* = 16.1 min), (**11**) (*t_R* = 18.3 min), and (**12**) (*t_R* = 16.9 min) were analyzed for ¹³C or deuterium incorporation.

In separate experiments, individual administration of (±)-[3-OC²H₃]secoisolariciresinols (**1-d₃**), (±)-[3-OC²H₃]matairesinols (**2-d₃**), (±)-[3-OC²H₃]pluviatolides (**6-d₃**), and (±)-[3,4-(OC²H₃)₂]burshehnins (**9-d₆**) was conducted exactly as above but scaled up proportionately ten times using ten shoots and the same concentration of the solutions. Following uptake, the shoots were metabolized for 7 d and then freeze-dried and extracted with hot MeOH. The MeOH extracts were treated with β -glucosidase and the reaction products were extracted with AcOEt as above.

The AcOEt extracts obtained after the administration of (±)-[3-OC²H₃]pluviatolides (**6-d₃**) and (±)-[3,4-(OC²H₃)₂]burshehnins (**9-d₆**) were treated with an excess of diazoethane followed by TLC separation (solvents: appropriate mixtures of AcOEt–CHCl₃) to give the following two fractions: Fr. 1 corresponding to 4-demethyleatein (**8**) and 5-demethyleatein (**10**), and Fr. 2 corresponding to 5-hydroxypluviatolide (**7**) and yatein (**11**). The whole of each fraction was then dissolved in 14 μ l of BSA for 45 min at 60 °C⁴⁴ and analyzed by GC-MS. At the retention times corresponding to the authentic ethylated lignans (±)-4,5-diethyl-5-hydroxypluviatolides (4,5-DiEt-**7**) (*t_R* = 18.6 min), (±)-4-ethyl-4-demethyleateins (4-Et-**8**) (*t_R* = 18.5 min), (±)-[3,4-(OC²H₃)₂]-5-ethyl-5-demethyleateins (5-Et-**10-d₆**) (*t_R* = 18.3 min), and (±)-yateins (**11**) (*t_R* = 18.3 min), mass spectra were analyzed for deuterium incorporation.

The AcOEt extracts so obtained following administration of (±)-[3-OC²H₃]secoisolariciresinols (**1-d₃**) and (±)-[3-OC²H₃]matairesinols (**2-d₃**) were submitted individually to TLC separation (solvents: appropriate mixtures of AcOEt–CHCl₃) to give the following three fractions: Fr. 1 corresponding to pluviatolide (**6**), 4-demethyleatein (**8**), burshehnin (**9**), 5-demethyleatein (**10**), and yatein (**11**); Fr. 2 corresponding to matairesinol (**2**), 5-methylthujaplicatin (**4**), 4,5-dimethylthujaplicatin (**5**), 5-hydroxypluviatolide (**7**), and 4-methylthujaplicatin (**12**); and Fr. 3 corresponding to secoisolariciresinol (**1**) and thujaplicatin (**3**). The whole of each fraction was then dissolved in 14 μ l of BSA for 45 min at 60 °C⁴⁴ and subjected to GC-MS analysis to determine deuterium incorporation into lignans.

Administration of L-[ring-¹³C₆]phenylalanine: L-[ring-¹³C₆]phenylalanine (1.0 mg) was dissolved in 0.1 M KPB buffer (pH 7.0, 217.0 μ l), and administered to ten young shoots. Following uptake and metabolism for 7 d, the plant materials were submitted to GC-MS analysis after TLC purification exactly as above. Simultaneous administration of two distinct lignans: A solution of a mixture of (±)-[3-OC²H₃]pluviatolides (**6-d₃**) (2.0

mg) and (\pm)-[7,7- $^2\text{H}_2$, 3-OC $^2\text{H}_3$]secoisolariciresinols (**1-d₅**) (2.0 mg) in a mixture of DMSO (620 μl) and distilled water (4380 μl) was administered to ten young shoots of *A. sylvestris*. Following uptake and metabolism for 7 d, the plant materials were treated with β -glucosidase and were submitted to GC-MS analysis after TLC purification exactly as above. Simultaneous administration of (\pm)-[3-OC $^2\text{H}_3$]thujaplicatins (**3-d₃**) and (\pm)-[7,7- $^2\text{H}_2$, 3-OC $^2\text{H}_3$]secoisolariciresinols (**1-d₅**) were conducted exactly as above.

Acknowledgements

This research was partly supported by Grants-in-Aid for Scientific Research (Nos. 1066016666, 12660150) and the Encouragement for Young Scientists (No. 4542) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and by a grant from the New Energy and Industrial Technology Development Organization. The authors thank Jacqueline Leshkevich for valuable comments on English writing.

References

- 1 T. Umezawa, *Regul. Plant Growth Dev.*, 2001, **36**, 57.
- 2 W. D. MacRae and G. H. N. Towers, *Phytochemistry*, 1984, **23**, 1207.
- 3 *Lignans. Chemical, biological and clinical properties*, ed. D. C. Ayres and J. D. Loike, Cambridge University Press, Cambridge, 1990.
- 4 D. L. Sackett, *Pharmacol. Ther.*, 1993, **59**, 163.
- 5 C. Canel, R. M. Moraes, F. E. Dayan and D. Ferreira, *Phytochemistry*, 2000, **54**, 115.
- 6 T. Umezawa, *Mokuzai Gakkaishi*, 1996, **42**, 911.
- 7 R. M. Moraes, C. Burandt Jr., M. Ganzera, X. Li, I. Khan and C. Canel, *Econ. Bot.*, 2000, **54**, 471.
- 8 R. R. J. Arroyo, W. Alfermann, M. Medarde, M. Petersen, N. Pras and J. G. Woolley, *Phytochem. Rev.*, 2002, **1**, 27.
- 9 D. E. Jackson and P. M. Dewick, *Phytochemistry*, 1984, **23**, 1037.
- 10 D. E. Jackson and P. M. Dewick, *Phytochemistry*, 1984, **23**, 1029.
- 11 W. M. Kamil and P. M. Dewick, *Phytochemistry*, 1986, **25**, 2093.
- 12 W. M. Kamil and P. M. Dewick, *Phytochemistry*, 1986, **25**, 2089.
- 13 A. J. Broomhead, M. M. A. Rahman, P. M. Dewick, E. E. Jackson and J. A. Lucas, *Phytochemistry*, 1991, **30**, 1489.
- 14 N. G. Lewis and L. B. Davin, in *Comprehensive Natural Products Chemistry*, vol. 1, ed. U. Sankawa, 1999, p. 639.
- 15 M. Petersen and A. W. Alfermann, *Appl. Microb. Biotechnol.*, 2001, **55**, 135.
- 16 G. A. Molog, U. Empt, S. Kulmann, W. van Uden, N. Pras, A. W. Alfermann and M. Petersen, *Planta*, 2001, **214**, 288.
- 17 S. Kuhlmann, K. Kranz, B. Lücking, A. W. Alfermann and M. Petersen, *Phytochem. Rev.*, 2002, **1**, 37.
- 18 H. Erdtman and J. Harmatha, *Phytochemistry*, 1979, **18**, 1495.
- 19 W.-J. Hu, S. A. Harding, J. Lung, J. L. Popko, J. Ralph, D. D. Stokke, C. J. Tsai and V. L. Chiang, *Nat. Biotechnol.*, 1999, **17**, 812.
- 20 T. Noguchi and M. Kawanami, *Yakugaku Zasshi*, 1940, **60**, 629.
- 21 M. Kozawa, N. Morita and K. Hata, *Yakugaku Zasshi*, 1978, **98**, 1486.
- 22 T. Kurihara, M. Kikuchi and S. Suzuki, *Yakugaku Zasshi*, 1978, **98**, 1586.
- 23 R. Ikeda, T. Nagao, H. Okabe, Y. Nakano, H. Matsunaga, M. Katano and M. Mori, *Chem. Pharm. Bull.*, 1998, **46**, 871.
- 24 R. Ikeda, T. Nagao, H. Okabe, Y. Nakano, H. Matsunaga, M. Katano and M. Mori, *Chem. Pharm. Bull.*, 1998, **46**, 875.
- 25 D. Koh and Y. Lim, *Agric. Chem. Biotechnol.*, 1999, **42**, 208.
- 26 S. Suzuki, N. Sakakibara, T. Umezawa and M. Shimada, *J. Wood Sci.*, 2002, **48**, 536.
- 27 Y.-H. Leem, M.-J. Lim, D.-H. Shin, H.-B. Chang, S.-W. Hong, E.-Y. Moon, D.-K. Lee, S.-J. Yoon and W.-S. Woo, *Arch Pharm Res.*, 1999, **22**, 208.
- 28 A. Pelter, *J. Chem. Soc. (c)*, 1968, 74.
- 29 T. Umezawa, L. B. Davin, E. Yamamoto, D. G. I. Kingston and N. G. Lewis, *J. Chem. Soc., Chem. Commun.*, 1990, 1405.
- 30 T. Umezawa, L. B. Davin and N. G. Lewis, *J. Biol. Chem.*, 1991, **226**, 10210.
- 31 Z.-Q. Xia, M. A. Costa, H. C. Pélissier, L. B. Davin and N. G. Lewis, *J. Biol. Chem.*, 2001, **276**, 12614.
- 32 S. Suzuki, T. Umezawa and M. Shimada, *Biosci. Biotechnol. Biochem.*, 2002, **66**, 1262.
- 33 T. Okunishi, N. Sakakibara, S. Suzuki, T. Umezawa and M. Shimada, *J. Wood Sci.*, in press.
- 34 M. Osuka, M. Suzuki, T. Kihara, S. Enomoto, S. Kawai, H. Ohashi, H. Koyama and T. Hara, the 46th Lignin Symposium Abstracts, 2001, p. 105.
- 35 V. Seidel, J. Windhövel, G. Eaton, A. W. Alfermann, R. R. J. Arroyo, M. Medarde, M. Petersen and J. G. Woolley, *Planta*, 2002, **215**, 1031.
- 36 Z.-Q. Xia, M. A. Costa, J. Proctor, L. B. Davin and N. G. Lewis, *Phytochemistry*, 2000, **55**, 537.
- 37 T. Umezawa, T. Isohata, H. Kuroda, T. Higuchi and M. Shimada, Chiral HPLC and LS-MS analysis of several lignans, *Biotechnology in pulp and paper industry*, ed. M. Kuwahara, M. Shimada, Uni, Tokyo, 1994, pp. 507–512.
- 38 N. Takaku, D.-H. Choi, K. Mikame, T. Okunishi, S. Suzuki, H. Ohashi, T. Umezawa and M. Shimada, *J. Wood Sci.*, 2001, **47**, 476.
- 39 T. Okunishi, N. Takaku, P. Wattanawikit, N. Sakakibara, S. Suzuki, F. Sakai, T. Umezawa and M. Shimada, *J. Wood Sci.*, 2002, **48**, 237.
- 40 E. Brown and A. Daugan, *Heterocycles*, 1987, **26**, 1169.
- 41 S. K. Banerjee, M. Manolopoulou and J. M. Pepper, *Can. J. Chem.*, 1962, **40**, 2175.
- 42 J. M. Pepper and J. A. MacDonald, *Can. J. Chem.*, 1952, **31**, 476.
- 43 K. Mikame, N. Sakakibara, T. Umezawa and M. Shimada, *J. Wood Sci.*, 2002, **48**, 440.
- 44 T. Umezawa, H. Kuroda, T. Isohata, T. Higuchi and M. Shimada, *Biosci. Biotechnol. Biochem.*, 1994, **58**, 230.